Cleveland Clinic; Taussig Cancer Institute

Cleveland, Ohio 44195-0001

9 studies enrolling now · 51 studies all time

What they study most

AML With Mutated NPM1, Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, Adult Soft Tissue Sarcoma, Advance Malignancies, Advanced Cancers Associated With Mesothelin Expression, Advanced Solid Tumor, Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumors, Angiomatoid Fibrous Histiocytoma, Antimetabolites, Antineoplastic

Studies at this site

• Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery — Recruiting now
• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis — Recruiting now
• SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma — Recruiting now
• A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Recruiting now
• A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML — Recruiting now
• A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors — Recruiting now
• A Phase 1 Study of LNCB74 in Advanced Solid Tumors — Recruiting now
• Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) — Recruiting now
• Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors — Recruiting now
• A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy — Running, not enrolling
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer — Running, not enrolling
• A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment — Completed
• Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) — Completed
• Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors — Running, not enrolling
• Expanded Access of Sotorasib — NO_LONGER_AVAILABLE
• A Study of SEA-CD40 Given With Other Drugs in Cancers — Completed
• Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma — Stopped early
• MEN1703 (SEL24) in Participants With Acute Myeloid Leukemia — Completed
• Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer — Completed
• Safety of Pregnancy in BRCA Mutated Breast Cancer Patients — Completed
• A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck — Stopped early
• A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms — Stopped early
• Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression — Completed
• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma — Completed
• Compassionate Use Study of Tenalisib (RP6530) — Completed
• Preoperative vs Postoperative IMRT for Extremity/Truncal STS — Running, not enrolling
• Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer — Completed
• Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas — Status unconfirmed
• Study to Evaluate the Safety and Tolerability of Brexucabtagene Autoleucel (KTE-X19) in People With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma — Stopped early
• Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension — Completed
• Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) — Completed
• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH — Stopped early
• OLAParib COmbinations — Stopped early
• Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis — Stopped early
• Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma — Completed
• Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer — Completed
• A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes — Completed
• NEXT: Subsequent Exposure to Tyrosine Kinase Inhibition at Recurrence After Adjuvant Therapy in Renal Cell Carcinoma — Stopped early
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) — Completed
• Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) — Completed
• A Study to Estimate the Effect Sizes of HRCT Endpoints in Response to Glucocorticoid Induction Therapy in Subjects With Pulmonary Sarcoidosis — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors — Stopped early
• Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer — Completed
• Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib — Stopped early
• Safety, Tolerability & PK of KX2-361 in Subjects w Adv. Malignancies Refractory to Conventional Therapies — Completed
• A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer — Completed
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma — Completed
• Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy — Completed